eISSN: 1897-4252
ISSN: 1731-5530
Kardiochirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
3/2019
vol. 16
 
Share:
Send email
Share:
abstract:
Letter to the Editor

Bilateral lung transplantation in cystic fibrosis with hepatitis C infection – a study of two cases

Nikola Ruszel
1
,
Bartosz Kubisa
2
,
Piotr Lisowski
1
,
Maria Piotrowska
2
,
Michał J. Kubisa
1
,
Mirosław Brykczyński
3
,
Małgorzata Wojtyś
2
,
Jarosław Pieróg
2
,
Michalina Czarnecka
2
,
Janusz Wójcik
2
,
Norbert Wójcik
2
,
Piotr Sielicki
3
,
Michał Bielewicz
2
,
Tomasz Grodzki
2

  1. Students’ Research Club of the Department of Thoracic Surgery and Transplantation, Pomeranian Medical University, Szczecin, Poland
  2. Department of Thoracic Surgery and Transplantation, Pomeranian Medical University, Szczecin, Poland
  3. Department of Cardiac Surgery, Pomeranian Medical University, Szczecin, Poland
Kardiochir Torakochir Pol 2019; 16 (3): 133-135
DOI: https://doi.org/10.5114/kitp.2019.88603
Online publish date: 2019/10/28
View full text Get citation
 
PlumX metrics:
Cystic fibrosis (CF) is one of the most common hereditary diseases in Caucasians – it affects more than 70 000 patients worldwide [1]. Mutation in the CFTR gene leads to inappropriate synthesis of the chloride anion channel, which interferes with the regular function of multiple organs. Pulmonary-wise, CF manifests by the presence of thick, immobile secretions in the lungs, which increases the incidence of respiratory tract infections. Median survival rate for patients in the last decades has increased – over a half of the children with CF, born between 2013 and 2017, are expected to live 44 years or more [1]. The development of pharmacotherapy and a variety of remedial solutions give a high chance for longer survival of CF patients, and it is predicted that the number of effectively cured adults will continue to grow in future. However, some CF patients require a more radical life-saving solution to tackle the respiratory insufficiencies – lung transplantation (LuTx). Identification of transplant candidates is still an evolving discipline which aims to provide the best survival benefit for all of the patients qualified for this procedure [2].
In this Letter, the history of two male patients who underwent a double LuTx (1st in 2015; 2nd in 2016) after eradication of hepatitis C virus (HCV) infection will be presented. Their cases were the first of this kind in Poland. As seen in the case of patient 1, a carefully planned operation and intensive care after the procedure can lead to satisfactory therapeutic results and significant improvement of the life standard of critically ill patients. However, LuTx can also be a highly challenging procedure. As was seen in the case of patient 2, asymmetry of the native lungs, hilar fibrosis and the risk of potential HCV viral multiplication lead to repetitive exclusion of the patient from this procedure in multiple centers in Europe and United States. However, LuTx was performed with a therapeutic outcome surpassing initial predictions.
The main intention of lung transplantation was to improve the outcomes in patients suffering from end-stage lung disease. The most important indications for LuTx referral and the factors which may be further related to post-transplantation survivorship are presented in Table I.
In accordance with the International Society for Heart and Lung Transplantation [3], the main indications for LuTx referral in the presented CF patients were: forced expiratory volume in 1 s...


View full text...
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.